^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Cholangiocarcinoma
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

    Excerpt:
    ...- Patients must have either IDH1 or IDH2 mutations (any known mutations) based on the SNaPshot platform or other molecular testing platform from either archived tissue or fresh biopsy (tested in CLIA-certified lab)...
    Trial ID:
    NCT02428855
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Discov
    Title:

    Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma

    Excerpt:
    Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations....A broad range of responses to the different agents was observed across the cell line collection, with specific activity profiles for different BTC subtypes... the IDHm ICC lines were marked outliers in their response to the multi-tyrosine kinase inhibitor (TKI), dasatinib.
    DOI:
    10.1158/2159-8290.CD-15-1442